

# Q12025 Earnings Presentation

May 14, 2025






### Disclaimer

This presentation contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Forward–looking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", approximate", expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "would" and similar expressions. Forward–looking statements and information are provided for the purpose of providing information about the current expectations and plans of the management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward–looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.


Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with: primary healthcare sector in general; competition; that future results may vary from historical results; the availability and effective integration and operation of management information systems and other technologies; ability to mitigate against cyber security risks; ability to access sufficient capital from internal and external sources; changes in legislation, including but not limited to tax laws; and government regulations. Accordingly, readers should not place undue reliance on the forward–looking statements, timelines and information contained in this presentation. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this presentation are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events, or otherwise, unless so required by applicable securities laws or the TSX Exchange. The forward-looking statements or information contained in this presentation are expressly qualified by this cautionary statement. The TSX Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this presentation.

## The WELL Health Family – Today



### The WELL Health Family – Future State



## WELL Q1 2025 Key Financial Highlights

**Q1** Revenue

\$294.1M

+32% Y/Y

Q1 Adj. EBITDA

\$27.6M

+36% Y/Y

WELL Canada Revenue Growth

**Total** Organic

+32% +13%

Q1 Revenue exc. CM Impact

\$300.7M

+30% Y/Y

Q1 Adj. EBITDA exc. CM

\$34.1M

+21% Y/Y

WELL Canada Adj. EBITDA

\$18.7M

+29% Y/Y



### **WELL Q1 2025 Operational Highlights**

4,300+

Providers in WELL's Clinic
Network

42,000+

Unique Providers supported by WELL's Technology

2.5M+

Total Care Interactions +34% YoY (+27% organic)

1.6M+

Patient visits +24% YoY (+14% organic) +30%

YoY CAN patient visit growth (+12% organic)

16%

YoY US patient visits growth (all organic)



## Q1-2025 Earnings – Additional Topics to be Covered

### Key updates on the following:

- 1. HEALWELL AI
- 2. WELLSTAR
- 3. Canadian Clinics Update
- 4. Strategic Sales Processes at Wisp and Circle Medical

### **HEALWELL AI Value Creation Timeline**

WELL Executed on an Intentional "Path to Control" Strategy and Played a Meaningful Role in The Development of the HEALWELL Al Story

July 20, 2023

\$0.0M

WELL acquires MCI clinics in ON, and agrees to invest in MCI to boost AI disease detection (Share price = 13.5¢/share) October 17, 2023

\$0.2M

Bought deal financing priced at \$0.60/share

February 1, 2024

-\$8.6M

\$3.6M in cash and \$5.0M in a promissory note received from the sale of IntraHealth to HEALWELL

March 26, 2025

\$4.4M

Exercise of convertible debentures and outstanding warrants

19 Months

Since the launch of HEALWELL on October 1, 2023

\$150M+

Total Capital Raised at HEALWELL

October 1, 2023

\$4.0M

MCI is renamed HEALWELL and \$10M recapitalization financing transaction is closed. Call option for Class A Shares established for WELL December 22, 2023

\$0.5M

Bought deal financing priced at \$0.80/share, and an additional warrant priced at \$1.20/share

January 21, 2025

\$1.0M

Bought deal financing to support the acquisition of Orion Health priced at \$2.00/share

April 1, 2025


\$3.9M

Call option for Class A Shares exercised \$160M+

Annual Revenue Run-Rate


\$5.4M

Net Cash Invested by WELL<sup>1</sup>





### **HEALWELL AI <> Value Creation Journey for WELL Shareholders**



\$129M+

Of Shareholder Value Created For WELL Shareholders

49¢/Share

Of Shareholder Value Created For WELL Shareholders

5.5x

Multiple on Invested Capital



<sup>1)</sup> Net amount invested includes the net cash invested, and the vend-in equity value related to the sale of IntraHealth.

<sup>2)</sup> Based on AIDX share price of \$1.63

# **WELLSTAR** Delivering on Growth and Profitability


WELLSTAR exists to enable healthcare practitioners to provide the highest-quality care with best-in-class technology and services







### **WELL Canadian Clinics Financial Performance**







220

### WELL Canadian Clinic M&A Track Record

#### **Deal and Effective Total Consideration/Sh. EBITDA Multiples**



Total Consideration	\$22.4M	\$230.3M	\$5.8M	\$7.4M	\$14.8M
Number of Transactions	6	5	4	6	10
Acquired Revenue	\$39M	\$105M	\$20M	\$57M	\$53M
Adj. EBITDA Growth <sup>4</sup> (%)	73%	47%	164%	nmf <sup>3</sup>	68%

\$280.7M	\$64.5M	
31	30	
\$273M	\$173M	
73%	121%	



<sup>1)</sup> Excludes one-time bad debt expense.

<sup>2)</sup> Effective multiple is based on Q1-2025 Run rate Adj. EBITDA.

Deal Adj. EBITDA for the 2023 cohort was negative.


<sup>4)</sup> Adj. EBITDA growth excludes one-time clinic transformation costs and shared services.


### **WELL Providers Are Seeing more Patients**

WELL Canadian Clinics
Patient Visits

Billable Providers in WELL's Canadian Clinics Network

#### **Commentary**





- WELL had 1,116 physicians in its network at the end of Q1 2025, representing more than 1% of all physicians in Canada
- The average WELL physician is seeing more patients per quarter than the same quarter last year.
- Q1 2023 = 421 patients visits/provider
- Q1 2024 = 433 patient visits/provider
- Q1 2025 = 509 patient visits/provider



### WELL Canada Experiencing Accelerating Growth

WELL Canada

Quarterly Revenue Growth




# WELL Canada Quarterly Adj. EBITDA Growth





## WELL Canada's Steady History of Improved A.EBITDA Growth



### **Canadian Clinic Recent M&A Activity**

Q4-2024 Q1-2025

**+20 Clinics**(1)

4 transactions

+\$30.8M

**Annual Revenue** 

+111 Providers(1)

**Total Canadian Clinics** 

+11 Clinics

4 transactions

+\$31.5M

**Annual Revenue** 

+71 Providers

**Total Canadian Clinics** 



## **M&A Pipeline**

WELL continues to execute on a robust pipeline, driving growth and sustaining strong operational momentum.

Under LOI: Canadian Clinics

\$44M Revenue

**8** Signed LOIs

10 Clinics

Under LOI: Total WELL<sup>1</sup>

\$65M

Revenue

11
Signed LOIs

Total WELL Pipeline

~\$360M

Revenue

35+
Targets Engaged

130+
Clinics

1) The Total WELL Pipeline includes potential deals that are either under LOI or in the pre-LOI stage.




### **Update on Wisp and Circle Sale Processes**






# Q1-2025 Financial Highlights

#### Revenue (IFRS)




#### Adj. EBITDA






## Q1-2025 Financial Highlights – Adj. Net Income

Revenue recognition impacts from Circle Medical had a material impact on Q1-2025 Net Income






<sup>(2)</sup> Q1-2024 Adj. Net Income was impacted by the sale of IntraHealth and a retro payment in WELL's diagnostic business



## Q1-2025 Financial Highlights – FCFA2S

Revenue recognition impacts from Circle Medical had a material impact on Q1-2025 Net Income





<sup>(1)</sup> Q1-2024 FCFA2S was impacted by a retro payment in its WELL Diagnostic Centres business.

<sup>(2)</sup> Change in Shareholder EBITDA excludes the impact of Circle Medical deferred revenue adjustments

### **Outlook: 2025 and Beyond**

2025 Guidance: \$1.40-1.45B Revenue \$190-210M Adj. EBITDA HEALWELL
Consolidation of
\$120M Revenue in 2025

WELL Canada >25% Adj. EBITDA Growth<sup>(1)</sup> for 2025

2025 Guidance exc. CM \$1.35-1.40B Revenue \$140-160M Adj. EBITDA Strategic Alternatives
Being Considered for All
US Care Business

WELL Canada
2-Yr Target<sup>(1)</sup> of
>\$800M Revenue
>\$100M Adj. EBITDA



# Contact

Hamed Shahbazi
CEO, Chairman & Founder
hamed@well.company

Tyler Baba Investor Relations investor@well.company

www.well.company 550-375 Water Street Vancouver, BC V6B 5C6 Canada

